Skip to content

Clinical study on the effect of acupuncture on peripheral amyloid clearance in patients with mild to moderate Alzheimer's disease

Clinical study on the effect of acupuncture on peripheral amyloid clearance in patients with mild to moderate Alzheimer's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17010465
Enrollment
Unknown
Registered
2017-01-18
Start date
2015-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

alzheimer‘s disease

Interventions

acupuncture group:acupuncture treatment three times per week
donepezil hydrochloride group:once daily, 5 mg/day for the first 4 weeks and 10 mg/day thereafter

Sponsors

First Teaching Hospital Of Tianjin University Of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
54 Years to 87 Years

Inclusion criteria

Inclusion criteria: Diagnostic criteria designed to identify patients with probable AD were developed by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimers Disease and Related Disorders Association criteria (NINCDS-ADRDA). The patients included in this study were required to have a MMSE score between 10 and 23, a 17-item Hamilton Depression Scale score =17, a Hachinski Ischemic Scale (HIS) score=4, and have a reliable caregiver who is able to accompany the participant to all study visits

Exclusion criteria

Exclusion criteria: Individuals were excluded if they had evidence of other diseases which could lead to dementia other than AD; significant unstable psychiatric or neurologic disorders; clinically relevant uncontrolled or unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular disease; clinically significant obstructive pulmonary disease; B12 or folic acid deficiency; alcoholism or drug misuse or current systemic illness influencing cognitive assessment; a history of hematologic and oncologic disorders in the past two years. Subjects could not participate if they had received any treatments which probably improve cognitive function and known sensitivity to acupuncture. Patients were also excluded from the study if they were incapable of giving informed consent or participated in any tests within the past 3 months.

Design outcomes

Primary

MeasureTime frame
Alzheimer’s disease Assessment Scale-Cognitive Subscale;Clinician’s Interview-Based Impression of Change-Plus Caregiver Input;

Secondary

MeasureTime frame
23-Item Alzheimer's disease Cooperative Study Activities of Daily Living Scales;Neuropsychiatric Index;plasma Aß40;plasma Aß42;plasma Aß Oligomer;urine Aß40;urine Aß42;Faeces Aß40;Faeces Aß42;

Countries

China

Contacts

Public ContactJingxian Han

First Teaching Hospital Of Tianjin University Of Traditional Chinese Medicine

hanjingxian6@163.com+86 022-27432003

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 8, 2026